Efforts in Anti-SARS-CoV-2 Drug Discovery Keep Creative Biolabs Moving Forward

May 16 03:45 2023
Creative Biolabs, conforming to the current research focus, allocates more resources to provide solutions supporting anti-SARS-CoV-2 drug discovery.

New York, USA – May 15, 2023 – Lately lifted requirement of demanded Covid vaccination on arrival in the USA presents a sign that, under the long-term COVID-19 pandemic, the main position of vaccine discovery is gradually biased towards the antiviral drug development against SARS-CoV-2.

Creative Biolabs relies on its extensive experimental experience to achieve a reasonable allocation in the SARS-CoV-2 vaccine discovery and novel antiviral drug development in the three-year COVID-19 outbreak.

An expert who specializes in the antiviral drugs at Creative Biolabs said, “Faced with the status quo of global infection, Creative Biolabs continues to focus on the discovery and development of SARS-CoV-2 drugs.”

At the present stage, the anti-SARS-CoV-2 drug services supported by Creative Biolabs include but are not limited to high-throughput screening of new drug candidates, inhibitor discovery, neutralizing antibody development, anti-viral peptide discovery, and broad-spectrum anti-viral drug discovery.

Inhibitor Discovery

The featured inhibitor discoveries for SARS-CoV-2 at Creative Biolabs include viral protease inhibitors, RNA synthesis inhibitors, and neuraminidase inhibitors. For more comprehensive services, a siRNA drug development platform has been cleverly established in the service section of RNA synthesis inhibitors.

SiRNA for treatment of SARS-CoV-2 offers a new approach to drug discoveries that treat COVID-19 infection,” the expert continued.

Based on previous hands-on experience, Creative Biolabs has designed a series of siRNAs targeting different sites of SARS-CoV-2 to inhibit coronavirus-induced cell death.

Neutralizing Antibody Development

Neutralizing antibodies (nAbs) commonly produce protective responses against most invading viruses. Creative Biolabs’ experts, supported by advanced technology platforms, have developed multiple neutralizing antibodies against SARS-CoV-2. For example, the SARS-CoV-2 mAb from humanized antibody mice has been produced from our self-cultivated humanized mice by immunizing them with the S-RBD protein antigen using hybridoma fusion schemes.

Neutralizing Antibody services of Creative Biolabs possess outstanding advantages, such as proprietary humanized antibody mouse models, mature hybridoma technology, and leading recombinant antibody technology, which help facilitate the experimental process for researchers worldwide.

Additionally, Creative Biolabs establishes yeast or phage display libraries for customers to identify specific peptide or antibody fragments in the development of anti-coronavirus candidate drugs.

High-Throughput Screening (HTS)

Versatile HTS methods supported by Creative Biolabs involve target-based screening, diversity and high-content screening, and RNA interference (RNAi).

“We use HTS to obtain effective drugs against SARS-CoV-2 by screening various approved drugs, inhibitors, proteins, and peptide libraries.”

The above-mentioned technical services are not exhaustive, and detailed information can be found at https://sars-cov-2.creative-biolabs.com.

About Creative Biolabs

In addition to collaborating with international researchers to combat the COVID-19 epidemic, Creative Biolabs is focusing on biomanufacturing, genomics, biofuels, nanotechnology, and cell treatment. On June 5th this year, Creative Biolabs will attend the 2023 BIO International Conference to speak with global experts and clients about a variety of life science topics.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://sars-cov-2.creative-biolabs.com